Literature DB >> 8983970

Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration.

A A Madu1, M Mayers, R Perkins, W Liu, G L Drusano, R Aswani, C N Madu, M H Miller.   

Abstract

The overall importance of the peak or the mean serum concentrations as predictors of ocular drug penetration is unknown. To address this fundamental question with an agent which shows promise as adjunctive therapy in the treatment of endophthalmitis, we studied the penetration of ciprofloxacin into the aqueous and vitreous humors following three different modes of systemic administration. New Zealand white rabbits received either a single bolus dose (40 mg kg-1), three intermittent doses of 13.33 mg kg-1 evenly spaced over an 8 hr period, or a continuous infusion of 40 mg kg-1 over an 8 hr period. Pharmacokinetic analysis was performed using RSTRIP II, a non-linear, least square regression model analysis program. The serum area under the concentration-time curve (AUC) values for each mode of drug administration were similar: 32.9 micrograms hr ml-1 for single dose, 31.9 micrograms hr ml-1 for intermittent dose, and 33.8 micrograms hr ml-1 for continuous infusion modes. The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion. The penetration into the aqueous and vitreous humors was not influenced by mode of administration. As with other quinolones we have studied, elimination rates were similar for the central and peripheral compartments in the post-distributive phase. Vitreous humor ciprofloxacin concentrations achieved were below that which inhibits most Staphylococcus epidermidis, the most common isolate in patients with post-operative endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983970     DOI: 10.1006/exer.1996.0101

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  5 in total

1.  Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.

Authors:  N Morlet; G G Graham; B Gatus; A J McLachlan; C Salonikas; D Naidoo; I Goldberg; C M Lam
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Subretinal fluid levels of topical, oral, and combined administered ciprofloxacin in humans.

Authors:  O Cekiç; C Batman; U Yaşar; N E Başci; O Zilelioğlu; A Bozkurt
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

3.  Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.

Authors:  W Liu; Q F Liu; R Perkins; G Drusano; A Louie; A Madu; U Mian; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

4.  Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil.

Authors:  Leonidas A Bourikas; George Kolios; Vassilis Valatas; George Notas; Ioannis Drygiannakis; Iordanis Pelagiadis; Pinelopi Manousou; Stefanos Klironomos; Ioannis A Mouzas; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

5.  Endogenous panophthalmitis in a patient with COVID-19 during hospitalization in an intensive care unit: A case report.

Authors:  Sinsucha Boontantrapiwat; Duangnate Rojanaporn; Weerawan Chokthaweesak; Naris Kitnarong
Journal:  Am J Ophthalmol Case Rep       Date:  2022-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.